Bcn Peptides S.a.

Lipotec, S.a.

Berta Ponsati Obiols

Jimena Fernández Carneado

Gemma Jodas Farres

Antonio Parente Dueña

Marc Gómez Caminals

Josep Farrera-Sinfreu

Francisco Javier Clemente Rodriguez

Antonio Vicente Ferrer Montiel

Cristina Carreño Serraïma

Wim Van Den Nest

Nuria Almiñana Domenech

Rafael Simó Canonge

Cristina Hernández Pascual

Antonio Ferrer Montiel

Marc Canas Poblet

Jordi Bacardit Cabado

Sergi Pavon Fernandez

Marcos Canas Poblet

Antonia Ribes Rubió

Laura Gort Mas

Leslie Matalonga Borrel

Ribera Jordana I Lluch

Josep Farrera Sinfreu

Rlbera Jordana I Lluch

Jimena Fernandez Carneado

Roberto Pascual Martínez

Raimon Rubires Ferrer

Jimena FERNÁNDEZ Carneado

Rafael SimÓ Canonge

Nuria ALMIÑANA Domenech

Christina CARREÑO Serraima

Maria CamprubÍ Robles

Cristina Carreno SERRAÏMA

Antonio Parente DUEÑA

Antonia Ribes Rubio

Roberto Pascual Martinez

Marc Gomez Caminals

Rafael Simo Canonge

Cristina Hernandez Pascual

Christina Carreno Serraima

Josep Farrera-sinfreu

The invention relates to cortistatin analogues and their uses. The compounds of the invention are peptide ligands with potential application in the diagnosis, prevention or therapy of those pathologies where receptors capable of binding to cortistatin, specific or shared with other molecules such as somatostatin and/or ghrelin (GHSR), are expressed, being in addition more stable in serum than cortistatin.

Cortistatin analogues for the treatment of inflammatory and/or immune diseases

The invention provides a therapy for lysosomal storage diseases and glycogenosis by treatment with compounds that promote exocytosis, preferably lysosomal exocytosis. The treatment of cells from patients affected by different lysosomal storage disorders with exocytosis activating compounds leads to a decrease in the accumulation of toxic substrate in the lysosomes, thus allowing the treatment, prevention and relief of the symptoms of many lysosomal storage disorders.

Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis

The invention relates to peptides of general formula (I):R-AA-R&#x2003;&#x2003;(I)which can regulate neuronal exocytosis, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or pharmaceutically acceptable salts thereof, wherein AA is a sequence of 3 to 40 adjacent amino acids contained in the amino acid sequence of the SNAP-25 protein, Ris selected from the group consisting of H or alkyl, aryl, aralkyl or acyl group; and Ris selected from the group consisting of amino, hydroxyl or thiol, substituted or non-substituted with aliphatic or cyclic groups, with the condition that when Ris H or acetyl, Ris not non-substituted amino, hydroxyl or thiol. The invention also relates to a method of obtaining such peptides, cosmetic or pharmaceutical compositions containing them and their use to treat those conditions requiring neuronal exocytosis regulation, preferably for treating the skin.

Neuronal exocytosis inhibiting peptides

A topical ophthalmic formulation of peptides and their use for the treatment and/or local prevention of ocular diseases, preferably posterior segment eye diseases.

Topical ophthalmic peptide formulation

Peptide derivatives, their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed.

Peptide ligands of somatostatin receptors

A stable pharmaceutical formulation for intravenous or intramuscular administration of Octreotide, which is characterized in that the vehicle for injection of the peptide or pharmaceutically acceptable salts thereof contains glycine in concentrations ranging from 10 to 60 mM and aqueous solution of hydrochloric acid in sufficient quantity to adjust the pH of the formulation to values between 3.0 and 4.2.

Stable pharmaceutical formulation for intravenous or intramuscular administration of active peptide compounds

A procedure for obtaining the somatostatin analog, octreotide by means of solid phase synthesis on polymer supports and by intervention of protector groups of the Fmoc/tBu type. It includes construction of the seven amino acid, Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)Thr(tBu)-Cys(Trt)-Cl-trityl-R linear peptide, in which R is a polymer; treatment of the resulting peptidyl-resin with acid, for detachment of the peptide from the resin; cycling the linear structure obtained by reaction with iodine before or after incorporation of the threoninol residue into the terminal carboxy end; incorporating the threoninol residue in solution upon the seven amino acid protected peptide with or without the disulfide bridge formed; and removing the protections at the N-terminus and at the side chains with a treatment with 70-95% TFA in presence of scavengers to obtain octreotide.

Procedure for obtaining the somatostatin analog, octreotide

A procedure for obtaining carbocalcitonin comprising the condensation of fragment 1, a docosapeptide corresponding to the carboxamide end of the carbocalcitonin sequence, conveniently protected and anchored on resin, with fragment 2 or 3, a nonapeptide corresponding to the amino end of the salmon calcitonin sequence, with a ready-formed cycle between the Asu and Ser residua, and the treatment of the complete peptide skeleton (fragment 6 or 7) with an acid to free the totally deprotected peptide from the resin. ##STR1##

Procedure for obtaining carbocalcitonin

Growing community of inventors

Barcelona, Spain

Berta Ponsati Obiols